TENX vs. CMMB, ASLN, HEPA, CYCN, BNOX, OBSV, CANF, TRVN, VCNX, and KTTA
Should you be buying Tenax Therapeutics stock or one of its competitors? The main competitors of Tenax Therapeutics include Chemomab Therapeutics (CMMB), ASLAN Pharmaceuticals (ASLN), Hepion Pharmaceuticals (HEPA), Cyclerion Therapeutics (CYCN), Bionomics (BNOX), ObsEva (OBSV), Can-Fite BioPharma (CANF), Trevena (TRVN), Vaccinex (VCNX), and Pasithea Therapeutics (KTTA). These companies are all part of the "pharmaceutical preparations" industry.
Chemomab Therapeutics (NASDAQ:CMMB) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk, community ranking and valuation.
Chemomab Therapeutics currently has a consensus price target of $6.50, suggesting a potential upside of 796.55%. Tenax Therapeutics has a consensus price target of $480.00, suggesting a potential upside of 13,233.33%. Given Chemomab Therapeutics' higher probable upside, analysts plainly believe Tenax Therapeutics is more favorable than Chemomab Therapeutics.
Chemomab Therapeutics' return on equity of -65.79% beat Tenax Therapeutics' return on equity.
Tenax Therapeutics received 125 more outperform votes than Chemomab Therapeutics when rated by MarketBeat users. However, 60.00% of users gave Chemomab Therapeutics an outperform vote while only 58.58% of users gave Tenax Therapeutics an outperform vote.
In the previous week, Chemomab Therapeutics had 4 more articles in the media than Tenax Therapeutics. MarketBeat recorded 4 mentions for Chemomab Therapeutics and 0 mentions for Tenax Therapeutics. Tenax Therapeutics' average media sentiment score of 0.50 beat Chemomab Therapeutics' score of 0.00 indicating that Chemomab Therapeutics is being referred to more favorably in the media.
46.1% of Chemomab Therapeutics shares are held by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are held by institutional investors. 11.9% of Chemomab Therapeutics shares are held by company insiders. Comparatively, 1.9% of Tenax Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Chemomab Therapeutics has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500. Comparatively, Tenax Therapeutics has a beta of 2.25, suggesting that its stock price is 125% more volatile than the S&P 500.
Summary
Chemomab Therapeutics and Tenax Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.
Get Tenax Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TENX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TENX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tenax Therapeutics Competitors List
Related Companies and Tools
